Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Long-Term Deferred Tax (2020 - 2025)

Neuroone Medical Technologies filings provide 6 years of Long-Term Deferred Tax readings, the most recent being $20.6 million for Q3 2025.

  • On a quarterly basis, Long-Term Deferred Tax rose 7.32% to $20.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $20.6 million, a 7.32% increase, with the full-year FY2025 number at $20.6 million, up 7.32% from a year prior.
  • Long-Term Deferred Tax hit $20.6 million in Q3 2025 for Neuroone Medical Technologies, up from $19.2 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $20.6 million in Q3 2025 to a low of $8.9 million in Q3 2021.
  • Median Long-Term Deferred Tax over the past 5 years was $15.4 million (2023), compared with a mean of $15.2 million.
  • Biggest five-year swings in Long-Term Deferred Tax: soared 55.81% in 2021 and later grew 7.32% in 2025.
  • Neuroone Medical Technologies' Long-Term Deferred Tax stood at $8.9 million in 2021, then skyrocketed by 35.9% to $12.1 million in 2022, then grew by 27.95% to $15.4 million in 2023, then rose by 24.22% to $19.2 million in 2024, then rose by 7.32% to $20.6 million in 2025.
  • The last three reported values for Long-Term Deferred Tax were $20.6 million (Q3 2025), $19.2 million (Q3 2024), and $15.4 million (Q3 2023) per Business Quant data.